Preoperative Docetaxel for Localized Progressive Castration-resistant Prostate Cancer (CRPC)
|ClinicalTrials.gov Identifier: NCT00811031|
Recruitment Status : Withdrawn
First Posted : December 18, 2008
Last Update Posted : July 30, 2012
- To evaluate the association of the probability of increase in phosphorylation of platelet-derived growth factor receptor (PDGFR) of > 0.5 in peripheral blood leucocytes following pre-operative docetaxel chemotherapy, with progression-free survival in localized castration-resistant prostate cancer (CRPC)
- To evaluate the association of the probability of increase in phosphorylated platelet-derived growth factor receptor (PDGFR) expression in peripheral blood leucocytes > 0.5 with indices of tumor regression including PSA-decline by 50% and measures of objective regression of tumor by transrectal MRI following pre-operative docetaxel therapy.
- Explore associations of probability of increase in phosphorylated PDGFR in peripheral blood leucocytes following pre-operative docetaxel therapy with plasma PDGF kinetics and spatial and quantitative PDGF and phosphorylated PDGFR expression in tumor and stromal compartments in resected specimens.
- Evaluate the association of probability of increase in phosphorylated PDGFR expression in peripheral blood leucocytes following pre-operative docetaxel chemotherapy with overall survival outcomes.
- Assess global quality of life measures at baseline and 6 and 12 months post-operatively.
- Create a tissue archive comprising tumor and peripheral blood specimens as a suitable resource for future genomic and proteomic studies.
|Condition or disease||Intervention/treatment||Phase|
|Prostate Cancer||Drug: Taxotere Drug: Prednisone||Phase 2|
Hide Detailed Description
The Study Drugs:
Docetaxel is designed to stop the growth of cancer cells, which may cause the cells to die. It is believed to be weakly effective at killing blood vessels in cancer cells as well.
Prednisone and docetaxel are commonly used to treat prostate cancer.
Study Drug Administration:
If you are found to be eligible to take part in this study, on Day 1 of every 21-day study "cycle", you will receive docetaxel through a needle in your vein over 1 hour.
Everyday, you will take prednisone by mouth 2 times a day (in the morning and evening). You should take prednisone with meals.
You will take dexamethasone by mouth at 12 hours and 6 hours before you receive docetaxel. This is to help reduce the risk of any allergic reaction and fluid retention. It is important that you take this drug on schedule.
On Day 1 of each cycle, the following tests and procedures will be performed:
- You will have a physical exam, including measurement of your weight.
- Your performance status will be recorded.
- You will be asked about any drugs or treatments you may be receiving.
- You will be asked about any side effects you have experienced since your last visit.
Blood (about 2 teaspoons) will be drawn for routine tests and to test for PSA and testosterone levels.
On Day 1 of Cycle 3, blood (about 2 teaspoons) will be drawn to test for PDGFR and PDGF levels.
If you complete 2 cycles or more, you will be eligible to have surgery as part of this study.
If you are eligible, no more than 21 days after your last dose of docetaxel, you will have surgery to remove your prostate gland. You will sign a separate consent for this surgery, which will describe the procedure and its risks in detail.
Before surgery, probably at your pre-surgical visit, blood (about 2 teaspoons) will be drawn to test for PDGFR and PDGF levels.
Length of Study:
You will take the study drug for up to 4 cycles before having surgery. You will be off study treatment after you have surgery. You will be taken off study early if you experience intolerable side effects or the disease gets worse.
This is an investigational study. Docetaxel given with prednisone is commercially available and FDA approved for the treatment of prostate cancer.
Up to 28 participants will take part in this study. All will be enrolled at M. D. Anderson.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Study of Pre-operative Docetaxel for Progressive Localized Castration Resistant Prostate Cancer|
|Experimental: Taxotere + Prednisone||
75 mg/m^2 Day 1 of every 21-day cycle by vein for 4 cycles prior to surgery.
Other Name: docetaxelDrug: Prednisone
5 mg twice a day by mouth.
- Pre-to-post chemotherapy increase phosphorylation of platelet-derived growth factor receptor (PDGFR) [ Time Frame: PDGFR will be estimated for each patient based on blood samples taken at day 0 and at day 42 using the Bayesian survival time regression model. ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00811031
|Principal Investigator:||Lance Pagliaro, MD||UT MD Anderson Cancer Center|